TNXP insider trading
NasdaqGS HealthcareTonix Pharmaceuticals Holding Corp. — scored insider trade history from SEC Form 4 filings, parsed and contextualised by FilingIQ.
About Tonix Pharmaceuticals Holding Corp.
Tonix Pharmaceuticals Holding Corp., a fully integrated biopharmaceutical company, develops and commercializes therapies for central nervous system (CNS) disorders, immunology and immuno-oncology, infectious diseases, and rare diseases in the United States. The company offers TONMYA, a cyclobenzaprine HCl sublingual tablet for the treatment of fibromyalgia. It also markets Zembrace SymTouch and Tosymra for the treatment of acute migraine with or without aura in adults. In addition, the company develops TNX-102 SL, a cyclobenzaprine HCl sublingual tablet for the treatment of major depressive disorder and acute stress reaction/acute stress disorder; TNX-1300, a double-mutant cocaine esterase for the treatment of cocaine intoxication; TNX-1500, an Fc-modified humanized monoclonal antibody to prevent kidney transplant rejection, as well as to treat autoimmune conditions; TNX-4800, a humanized monoclonal antibody for the seasonal prevention of Lyme disease; and TNX-2900, an intranasal oxytocin potentiated with magnesium for the treatment of Prader-Willi syndrome. Further, it is developing TNX-1900, an intranasal potentiated oxytocin for the treatment of binge eating disorder, adolescent obesity, and bone health in pediatric autism, and arginine-vasopressin deficiency; TNX-801, a live horsepox vaccine for the prevention of smallpox and mpox; TNX-4200, a small molecule broad-spectrum antiviral agent targeting CD45 for the treatment or prevention of viral disease; TNX-4900, a highly selective small-molecule Sigma-1 receptor antagonist for neuropathic pain; TNX-1700, a recombinant Trefoil Factor Family 2 fusion protein for the treatment of gastric and colorectal cancers; and TNX-1800 and TNX-1850, live modified horsepox vaccines for the prevention of COVID. Tonix Pharmaceuticals Holding Corp. was founded in 2007 and is based in Berkeley Heights, New Jersey.
Company website: www.tonixpharma.com
TNXP insider activity at a glance
FilingIQ has scored 159 insider transactions for TNXP since Feb 25, 2015. The most recent filing in our index is dated May 12, 2026.
Across the full history, 74 open-market purchases
and 7 open-market sales
were filed under transaction codes P and S respectively. Compensatory share awards
(code A) and option exercises (code M) are tracked separately and not counted here.
The average FilingIQ composite score on TNXP insider trades is 60.5/100, produced by FilingIQ's multi-factor Form 4 model. Model framework documented at methodology.
Latest TNXP Form 4 filings
Most recent disclosures. Sign up to filter by score, transaction code, or insider role.
Other Healthcare tickers with recent insider activity
Top insiders trading TNXP
Frequently asked
- How many insider trades does FilingIQ track for TNXP?
- FilingIQ tracks 159 Form 4 insider transactions for TNXP (Tonix Pharmaceuticals Holding Corp.), covering filings from Feb 25, 2015 onwards. 20 of those were filed in the last 90 days.
- Are TNXP insiders net buyers or net sellers?
- Across the full Form 4 history for TNXP, 74 transactions (47%) were open-market purchases and 7 (4%) were open-market sales. Compensatory awards and option exercises are filtered out of these counts.
- Where does TNXP insider data come from?
- Every transaction shown on this page is sourced directly from SEC EDGAR Form 4 filings. FilingIQ parses the raw XML, normalises insider identity across reporting variations, and scores each trade on its multi-factor composite model.
- What sector is TNXP in?
- Tonix Pharmaceuticals Holding Corp. (TNXP) is classified in the Healthcare sector, specifically Biotechnology, with a current market capitalisation of $198.59M.
Methodology & sources
Every TNXP insider transaction shown on FilingIQ is parsed directly from a public SEC Form 4 XML filing. Insider identity is normalised across reporting variants (CIK changes, name spellings, related-party indirect holdings). The FilingIQ composite score is documented in full on the team page and algo disclosure. Not investment advice; see disclaimer.